Table 3.

Clinical Trial Status of NLRP3 Inhibitors [110.1038/s41577-019–0165-0]

S. No	NLRP3 inhibitors	Mechanism of action	Clinical trial status
1	CY-09	Inhibitor of NACHT and ATPase	Phase II
2	Oridonin	Binds irreversibly with Cys27 residue of NLRP3 9 and inhibits the interaction of NLRP3–NEK7	Phase II
3	Tranilast	Binds with the NACHT and inhibits the interaction of NLRP3– NLRP3 and NLRP3-ASC	Approved
4	MNS	Inhibitor of NACHT and ATPase	Approved
5	OLT1177 (dapansutrile)	Inhibitor of NACHT and ATPase	Phase II
6	Bay 11–7082	Inhibitor of NACHT and ATPase	Phase II
7	BOT-4-one	Inhibitor of NACHT and ATPase	Phase II
8	Parthenolide	Inhibitor of NACHT ATPase and Caspase-1 inhibitor	Phase II
9	INF39	Inhibitor of NACHT and ATPase	Phase II
10	MCC950 (CP-456773)	Not known	Phase II